ACAD also had same thing. Abrupt departure of CMO and a director followed by a downgrade. I began to think if Alzheimer trial is not going well since this happened after they announced a plan to delay the study.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.